Compare
Oramed Pharmaceuticals Inc. vs Siga Technologies Inc vs Nature's Sunshine Products Inc vs Tonix Pharmaceuticals Holding Corp.
| Latest fiscal year | Oramed Pharmaceuticals Inc. ORMPRevenue covers only part of its income (partial revenue) | Siga Technologies Inc SIGA | Nature's Sunshine Products Inc NATR | Tonix Pharmaceuticals Holding Corp. TNXP |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $94.57M | $480.14M | $13.11M |
| Revenue growth (YoY) | n/a | -31.8% | +5.7% | +29.8% |
| Gross margin | n/a | 68.6% (computed) | 72.4% | 49.3% (computed) |
| Operating margin | n/a | 25.1% | 5.2% | -959.1% |
| Net margin | n/a | 24.6% | 4.3% | -946.2% |
| Net income | $64.05M | $23.28M | $20.45M | -$124.02M |
| EPS (Diluted) | $1.50 | $0.32 | $1.06 | -$14.57 |
| Operating cash flow | -$9.14M | $43.47M | $35.32M | -$99.84M |
| Free cash flow | -$9.15M | n/a | $28.84M | -$103.21M |
| Cash & equivalents | $45.95M | $154.97M | $93.89M | $207.64M |
| Total assets | $230.86M | $219.47M | $261.15M | $277.17M |
| Total liabilities | n/a | $20.65M | $99.59M | $32.02M |
| Shareholders' equity | $199.74M | $198.82M | $161.55M | $245.15M |
| Return on year-end equity | 32.1% | 11.7% | 12.7% | -50.6% |
| Shares outstanding | 39.28M | 71.61M | 17.51M | 12.79M |
Revenue, most recent five fiscal years
| Fiscal year | Oramed Pharmaceuticals Inc. | Siga Technologies Inc | Nature's Sunshine Products Inc | Tonix Pharmaceuticals Holding Corp. |
|---|---|---|---|---|
| Latest | n/a | $94.57M Ended 2025-12-31 | $480.14M Ended 2025-12-31 | $13.11M Ended 2025-12-31 |
| 1 year earlier | n/a | $138.72M Ended 2024-12-31 | $454.36M Ended 2024-12-31 | $10.09M Ended 2024-12-31 |
| 2 years earlier | n/a | $139.92M Ended 2023-12-31 | $445.32M Ended 2023-12-31 | $7.77M Ended 2023-12-31 |
| 3 years earlier | n/a | $110.78M Ended 2022-12-31 | $421.91M Ended 2022-12-31 | n/a |
| 4 years earlier | n/a | $133.67M Ended 2021-12-31 | $444.08M Ended 2021-12-31 | n/a |